Table IV.
Multivariate analysis for serologic response in HM patients in active treatment.
| Variable | Odds ratio | 95% CI | P |
|---|---|---|---|
| Sex | |||
| Male | 1 | 0·100 | |
| Female | 0·48 | 0·20–1·15 | |
| Age | |||
| <65 years | 1 | 0·812 | |
| ≥65 years | 0·89 | 0·35–2·30 | |
| Diagnosis | |||
| Hodgkin lymphoma | 1 | 0·002 | |
| Aggressive B‐cell lymphomas | 0·77 | 0·2–3·01 | |
| Indolent B‐cell lymphomas or B‐cell chronic lymphocytic leukaemia | 1·38 | 0·32–5·90 | |
| Multiple myeloma | 28·23 | 3·83–207·97 | |
| T‐cell lymphomas | 0·71 | 0·09–5·58 | |
| Disease status | |||
| Remission | 1 | 0·251 | |
| Active | 0·56 | 0·21–1·51 | |
| Type of treatment | |||
| Other therapies | 1 | <0·001 | |
| Anti‐CD20 antibody plus chemotherapy | 0·07 | 0·02–0·24 | |
| ALC | |||
| <800 cells/μl | 1 | 0·055 | |
| ≥800 cells/μl | 2·54 | 0·98–6·57 | |
| ANC | |||
| <1500 cells/μl | 1 | 0·961 | |
| ≥1500 cells/μl | 0·97 | 0·26–3·54 | |
| IgG | |||
| <600 mg/dl | 1 | 0·940 | |
| ≥600 mg/dl | 1·26 | 0·35–4·54 | |
| Not evaluable or not available | 1·11 | 0·20–6·19 | |
| IgA | |||
| <80 mg/dl | 1 | 0·577 | |
| ≥80 mg/dl | 1·69 | 0·44–6·45 | |
| Not evaluable or not available | 0·53 | 0·05–5·38 | |
| IgM | |||
| <40 mg/dl | 1 | 0·030 | |
| ≥40 mg/dl | 4·20 | 1·18–14·93 | |
| Not evaluable or not available | 13·31 | 1·00–177·50 |
ALC, absolute lymphocytic count; ANC, absolute neutrophilic count; CI, confidence interval; HM, haematological malignancy.